A Phase 1/2 Study Of Selinexor In Combination With Standard Of Care (Soc) Therapy For Actively Diagnosed Or Recurrent Glioblastoma Read more
Descartes-11 Consolidation Treatment In Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Read more
EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma Read more
A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) Read more
A Phase I/II Assessment Of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) And Anti-TGIT (BMS-986207) Read more
A Phase 1/2 Open-Label Study To Investigate The Safety And Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of TAK-573 As A Single Agent In Patients With Refractory Multiple Myeloma Read more
A Phase I In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AMG 176 In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma Read more
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2) Read more
